Vnitřní lékařství 4/2021

PŘEHLEDOVÉ ČLÁNKY Obrovskobuněčná arteriitida: kontroverzní otázky | 229 / Vnitř Lék 2021; 67(4): 224–229 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 7. Andersen T. Arteritis temporalis (Horton): a survey and a case with glaucoma. Acta Med Scand. 1947; 128: 151–178. 8. McMillan GC. Diffuse granulomatous aortitis with giant cells associated with partial rup- ture and dissection of the aorta. AMA Arch Pathol. 1950; 49(1): 63–69. 9. Olhagen B. Polymyalgia rheumatica: a form of senile arteritis? Acta Rheumatol Scand. 1963; 9: 157–164. 10. Hamrin B, Jonsson N, Landberg T. Arteritis in “polymyalgia rheumatica.” Lancet 1964; 1: 397–401. 11. Alestig K, Barr J.Giant-cell arteritis. A biopsy study of polymyalgia rheumatica, inclu- ding one case of Takayasu‘s disease. Lancet. 1963; 1(7293): 1228–1230. 12. Cantini F, Niccoli L, Storri L et al. Are Polymyalgia Rheumatica and Giant Cell Arteritis the Same Disease? Semin Arthritis Rheum 2004; 33(5): 294–301. 13. Kermani TA. Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? Int J Rheum Dis 2019; 22: 41–48. 14. Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arte- ritis and polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum. 2020; 50(5): 1040–1048. 15. Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017; 47(2): 253–256. 16. Mackie SL, Taylor JC, Haroon-Rashid L et al. Association of HLA-DRB1 amino acid resi- dues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemio- logical investigation. Arthritis Res Ther. 2015; 17(1): 195. 17. Verdijk RM, Ouwendijk WJD, Kuijpers RWAM, Verjans GMGM. No Evidence of Varice- lla-Zoster Virus Infection in Temporal Artery Biopsies of Anterior Ischemic Optic Neuro- pathy Patients With and Without Giant Cell Arteritis. J Infect Dis. 2021; 4; 223(1): 109–112. 18. Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM. Giant Cell Arteritis: From Patho- genesis to Therapeutic Management. Curr Treatm Opt Rheumatol. 2016; 2(2): 126–137. 19. Imai N, Kuroda R, Konishi T, Serizawa M, Kobari M. Giant cell arteritis: clinical features of patients visiting a headache clinic in Japan. Intern Med 2011; 50(16): 1679–1682. 20. Mollan SP, Paemeleire K, Versijpt J et al. European Headache Federation recommenda- tions for neurologists managing giant cell arteritis. J Headache Pain 2020; 21, 28. 21. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corti- costeroids: Results in 55 cases in which the lesion was proved at biopsy. J AmMed Assoc. 1957; 163(10): 821–827. 22. Singh AG, Kermani TA, Crowson CS et al. Visual manifestations in giant cell arteri- tis: trend over 5 decades in a population-based cohort. J Rheumatol 2015; 42: 309–315. 23. Patil P, Williams M, Maw WW et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015; 33 (2 Suppl 89): S-103-6. 24. Vodopivec J, Rizzo, III.JF. Ophthalmic manifestations of giant cell arteritis, Rheumato- logy 2018; 57: ii63–ii72. 25. Chen JJ, Leavitt JA, Fang C et al. Evaluating the Incidence of Arteritic Ischemic Op- tic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmolo- gy 2016; 123(9): 1999–2003. 26. Peral-Cagigal B, Pérez-Villar Á, Redondo-González LM et al. Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis. Med Oral Patol Oral Cir Bucal. 2018;23(3): e290–e294. 27. Larivière, Delphine et al. Extra-and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine 2014; 93(28): e265. 28. Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum. 1995; 24(6): 422–431. 29. Nuenninghoff DM, Hunder GG, Christianson TJ et al. Mortality of large-artery com- plication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 3532–3537. 30. Greigert H, Zeller M, Putot A et al. Myocardial infarction during giant cell arteritis: A co- hort study. Eur. J. Intern Med 2021; 17: S0953-6205(21)00038-8. 31. Zenone T. Fever of unknown origin in rheumatic diseases. Infect Dis Clin North Am. 2007; 21(4): 1115–1135, x–xi. 32. Milchert M, Brzosko M. Tunnel Vision in a Patient with Polymyalgia Rheumatica. J Rheu- matol. 2020; 47(1): 155–156. 33. Prior JA, Ranjbar H, Belcher J et al. Diagnostic delay for giant cell arteritis – a systema- tic review and meta-analysis. BMC Med 2017; 15: 120. 34. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al. The Ame- rican College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990; 33: 1122–1128. 35. Murchison AP, Gilbert ME, Bilyk JR et al. Validity of the American College of Rheumato- logy criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012; 154(4): 722–729. 36. van der Geest KSM, Wayel H, Abdulahad WV et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica, Rheumatology 2015; 54(8): 1397–1402. 37. Hellmich B, Agueda A, Monti S et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79 (1): 19–30. 38. Mackie SL, Dejaco C, Appenzeller S et al. British Society for Rheumatology guideli- ne on diagnosis and treatment of giant cell arteritis, Rheumatology 2020; 59(3): e1–e23. 39. Chu R, Foster C, Ali M et al. Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10- year retrospective review of medical records. Lancet Rheumatol 2020; 2(12): E 744–E 778. 40. Dasgupta B. Giant Cell Arteritis Guideline Development Group. Concise guidance: diagnosis and management of giant cell arteritis. Clin Med (Lond). 2010; 10(4): 381–386. 41. Stacy RC, Rizzo JF, Dean M, Cestari DM. Subtleties in the Histopathology of Giant Cell Arteritis. Seminars in Ophthalmology 2011; 26: 4–5, 342–348. 42. Dejaco C, Ramiro S, Duftner C et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice Ann Rheum Dis2018; 77(5): 636–643. 43. Luqmani R, Lee E, Singh S et al. The Role of Ultrasound Compared to Biopsy of Tem- poral Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnos- tic accuracy and cost-effectiveness study. Health Technol Assess. 2016; 20(90): 1–238. 44. Theunissen P, Kliffen M, Dees A. Giant-cell Arteritis of the Ovarian Arteries: A Rare Ma- nifestation of a Common Disease. Eur J Case Rep Intern Med. 2018; 5(5): 000779. 45. Blockmans, D. Use of FDG-PET Scan for the Assessment of Large Vessel Vasculitis. Curr Treat Options in Rheum 2016; 2: 153–160. 46. Ray-Chaudhuri N, Kiné DA, Tijani SO et al. Effect of prior steroid treatment on tem- poral artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002; 86(5): 530–532. 47. Achkar AA, Lie JT, Hunder GG, O‘Fallon WM, Gabriel SE. How does previous corticos- teroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994; 120(12): 987–992. 48. Narváez B, Bernad D, Roig-Vilaseca C et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007; 37: 13–19. 49. Hellmich B, Águeda AF, Monti S et al. Treatment of Giant Cell Arteritis and Takayasu Ar- teritis—Current and Future. Curr Rheumatol Rep 2020; 22, 84. 50. Strehl C, Bijlsma JWJ, de Wit M et al. Defining conditions where long-term gluco- corticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016; 75(6): 952–957. 51. Ponte C, Rodrigues AF, O’Neill L, Luqmani RA. Giant cell arteritis: Current treatment and management. World J Clin Cases 2015; 3(6): 484–494. 52. Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C, Warrington KJ. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. J Rheumatol. 2019; 46(5): 501–508. 53. Mahr AD, Jover JA, Spiera RF et al. Adjunctive Methotrexate for Treatment of Giant Cell Arteritis. An Individual Patient Data Meta-Analysis.Arth Rheum 2007; 56(8): 2789–2797. 54. Stone JH, Tuckwell K, Dimonaco S et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017; 27; 377(4): 317–328. 55. Harrington R, Al Nokhatha SA, Conway R. Biologic Therapies for Giant Cell Arteritis. Biologics. 2021; 15: 17–29. 56. Sugihara T, Hasegawa H, Uchida HA et al. Associated factors of poor treatment outco- mes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthri- tis Res Ther 2020; 22(72): 1–12. 57. Maleszewski JJ, Younge BR, Fritzlen JT et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated pa- tients. Mod Pathol. 2017; 30(6): 788–796. 58. Nesher G, Poltorak V, Hindi I et al. Survival of patient with giant cell arteritis: Impact of vision loss and treatment with aspirin. Autoimmun Rev. 2019; 18(8): 831–834. 59. Dinkin M, Johnson E. One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment. Curr Treat Options Neurol 2021; 23: 6. 60. Turesson C, Börjesson O, Larsson K, Mohammad AJ, Knight A. Swedish Society of Rheu- matology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteri- tis. Scand J Rheumatol. 2019; 48(4): 259–265. 61. Crow RW, Katz BJ, Warner JE et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci. 2009; 64(3): 365–369. 62. Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV et al. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2017; 46: 513–519. 63. Mohammad AJ, Nilsson JA, Jacobsson LT, Merkel PA, Turesson C. Incidence and mor- tality rates of biopsy-proven giant cell arteritis in southern Sweden. Ann Rheum Dis 2015; 74: 993–997.